Literature DB >> 15886119

The role of CD22 and other inhibitory co-receptors in B-cell activation.

Lars Nitschke1.   

Abstract

Inhibitory co-receptors downmodulate B-cell receptor (BCR) signalling by setting a signalling threshold that prevents overstimulation of B cells. Activation of these inhibitory co-receptors occurs by phosphorylation on their cytoplasmic inhibitory immunoreceptor tyrosine-based inhibition motifs (ITIMs), followed by recruitment of the tyrosine phosphatase SHP-1 or the lipid phosphatase SHIP, and depends on their association with the BCR. Recent evidence shows that B-cell signal inhibition is regulated by ligand binding of inhibitory receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886119     DOI: 10.1016/j.coi.2005.03.005

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  67 in total

1.  Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors.

Authors:  Lela Kardava; Susan Moir; Wei Wang; Jason Ho; Clarisa M Buckner; Jacqueline G Posada; Marie A O'Shea; Gregg Roby; Jenny Chen; Hae Won Sohn; Tae-Wook Chun; Susan K Pierce; Anthony S Fauci
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

3.  Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.

Authors:  Francesca Gasparrini; Christoph Feest; Andreas Bruckbauer; Pieta K Mattila; Jennifer Müller; Lars Nitschke; Dennis Bray; Facundo D Batista
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

4.  Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.

Authors:  Ngozi Monu; Alan B Frey
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

Review 5.  B cell modulation in rheumatology.

Authors:  Gregg J Silverman; Sahil Khanna
Journal:  Curr Opin Pharmacol       Date:  2007-07-10       Impact factor: 5.547

6.  Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation.

Authors:  Adam H Courtney; Erik B Puffer; Jason K Pontrello; Zhi-Qiang Yang; Laura L Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

7.  Identification of proteins with the CDw75 epitope in human colorectal cancer.

Authors:  Óscar Mariño-Crespo; Almudena Fernández-Briera; Emilio Gil-Martín
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

8.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 9.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 10.  [Novel B-cell directed strategies for the treatment of rheumatic diseases].

Authors:  I H Tarner
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.